About iGenomX

iGenomX delivers the industry’s fastest, easiest, and most affordable multiplex sequencing tools. Scientists around the world are using its RIPTIDE® High-Throughput Rapid Library Prep (HT-RLP) to maximize laboratory capacity and statistical power for population and disease genetics, agricultural, food safety, microbiome, and synthetic biology applications. The company was founded in 2012 to commercialize the core technology invented by scientists at The Scripps Research Institute. Based in San Diego, iGenomX supports its growing list of customers through its international sales and service operations, as well as a global network of distributors and commercial service providers.



Keith Brown

Founder & CEO


Daniel Salomon, M.D.

Chief Scientist


Steve Head, M.S.

Senior Scientist - Assay Development


Phillip Ordukhanian, Ph.D.

Senior Scientist, Biochemistry


Azeem Siddique, Ph.D.

Director of Research and Development

Nils Homer

Nils Homer, Fulcrum Genomics



Decky Goodrich

Vice President


Take Ogawa

Profile Paul 1

Paul Doran


Keith Brown

Founder and CEO of iGenomX

Mr. Brown has been with the company since operations began in January of 2014. A co-founder of the company, Mr. Brown currently holds the position of Chief Executive Officer. Previously, Mr. Brown served as Vice President of Sales for Complete Genomics Inc., a DNA sequencing company located in Silicon Valley. Complete genomics is the first company to offer whole human genome sequencing services on a proprietary sequencing platform. After the acquisition of Complete Genomics by BGI, Mr. Brown became CEO of the BGI Americas Corporation. Prior to joining Complete in 2011, Mr. Brown was the National Sales Director at RainDance Technologies, a small start-up founded by serial entrepreneur Jonathan Rothberg. At RainDance, Mr. Brown led the commercialization strategy for a novel micro-droplet PCR system, with applications in the burgeoning Next-Generation Sequencing Industry. Mr. Brown held that position at RainDance from 2007 through his departure in 2011 to join Complete Genomics. Prior to RainDance, Mr. Brown held sales and market development positions at Affymetrix, Inc., the leading supplier of DNA microarrays. Mr. Brown has held numerous positions at Li-Cor Biosciences, a manufacturer of automated DNA sequencing instrumentation, and at Chemicon International (acquired by Serologicals). Mr. Brown started his career as a molecular biologist at Chemicon International supporting the launch of PCR based assays for infectious disease and genetic disorders. Mr. Brown has four issued and eight patents pending in the field of nucleic acid analysis.

Kirk D. Malloy, Ph.D.

Dr. Malloy has held management and executive leadership positions in rapidly growing life science and diagnostics companies for over 20 years. He founded BioAdvisors in April 2016 which provides strategic consulting services to life science, diagnostics and genomics companies. He also currently serves as Lead Independent Director for Organovo (ONVO); corporate director for Nanostring Technologies (NSTG); Executive Chairman for Agilome; and as a member of the board of directors for Edico Genome, iGenomX and JumpCode Genomics.

For the previous 13 years, he was Senior Vice President and General Manager of Life Sciences and Applied Markets at Illumina, a leading developer and supplier of genetic analysis instrumentation, assays and software for the life science and diagnostics markets. In this role he ran the company’s largest business unit with a P&L of over $1B and was responsible for the company's core platform technologies. His business unit served the life sciences and applied markets (Agrigenomics, Micriobiology, Transplant Biology, Forensics, Complex Diseases and Healthy Clinical Genomes). He joined Illumina in 2002 and previously managed a team of 450 in 50 countries as Vice President of Global Customer Solutions and Vice President of Quality, building and leading the commercial support and training organization and a professional service business generating more than $150M in annual revenues.

Dr. Malloy earned his B.S. in Biology from the University of Miami, and his M.S. and Ph.D. from the University of Delaware and held post-doctoral and instructor positions at Boston University and Northeastern University. He completed a certification for Corporate Directors at UCLA’s Anderson School in 2012. He also serves on the Board of Trustees for the Pacific Ridge School, and is on the Dean’s Advisory Board for the University of Delaware. He has 12 peer-reviewed publications and book chapters, dozens of invited and contributed scientific presentations and has been a reviewer for various scientific journals.

Eugene Chen

Mr. Chen is a Managing Director at CWC Healthtech Partners, a leading investor in iGenomX. Eugene partnered with CWC HealthTech Advisors in January 2013 following two decades as an entrepreneur and venture capitalist focused on healthcare. Eugene is a founding principal of Medenovo, LLC, an investment firm focused on medical devices. He is co-founder and CEO of SPIWay, LLC, a neuro-endoscopy company, and co-founder and CEO of FRESCA Medical, a company developing a consumer friendly device for the treatment of sleep apnea. Previously, Eugene was founder/CEO of USGI Medical, a minimally-invasive-obesity-surgery company; a Venture Partner and entrepreneur-in-residence with Alta Partners, a venture capital firm located in California's Silicon Valley; General Manager/Sr. VP at Applied Medical Resources Corporation; and Founder/CEO of BioFlex/Kinesys Inc., a knee orthotics company. Eugene also serves as manager of TEKE, LLC, a medical device incubator; a board member of Microfabrica Inc.; and a member of the board of trustees of the Pacific Ridge School. Eugene holds an M.B.A. from the Anderson School at UCLA and a B.S. in Mechanical Engineering from Cornell University. He and his wife, Katie, live in Carlsbad with their two sons, with whom Eugene enjoys spending quality family time "fighting" at the local Tae Kwan Do studio.

Joel Rotroff

Before joining the board of iGenomX, Joel spent four years as an investment professional at Baird Venture Partners where he focused on venture and growth equity investments in life sciences tools & diagnostics, medical devices and healthcare services. During his time at Baird, Joel was involved in the investment in, and was an invitee of the Board of Accuri Cytometers (acquired by Becton Dickenson). He also was actively involved with the firm’s investments in Incept (acquired by Hologic) and Palyon Medical, as well as the fund’s successful raising of its third fund. Prior to Baird Venture Partners, Joel was an investment banking analyst in Piper Jaffray’s healthcare group where he was a member of deal teams that completed buy-side & sell-side transactions, primary offerings, secondary offerings and private raises. Before Piper Jaffray, Joel was an analyst in the Business Planning Group at Boston Scientific Corporation (BSX) where he evaluated internal research and development projects and acquisition integration. Joel also previously worked as a summer associate at Norwest Equity Partners (NEP) where he was involved in NEP’s investment in the Momentum group and worked with Surgical Investment Systems, a portfolio company of NEP. Joel holds a BS with honors and distinction in Biomedical Engineering from the University of Wisconsin, a Master of Engineering Management from Duke University and an MBA from Northwestern University’s Kellogg Graduate School of Business.

Kevin Li, Ph.D.

Dr. Kevin Li is a Managing Partner at LYZZ Capital, a healthcare-focused venture capital/PE fund investing globally in leading biotech and pharmaceutical companies.  Kevin has been an active biotech investor in the US and China for over fifteen years. Prior to co-founding LYZZ, he was a partner at DT Capital and HBM BioMed China. Earlier in his career, Kevin was involved in the building and management of several successful biotech companies, including GenoSpectra, Fountain Medical Development, Amazin Biotech. Dr. Li received his Ph.D. in biology from Indiana University and was a postdoctoral fellow at Stanford University School of Medicine.

Dr. Li has been an investor and board member of a number of successful biomedical companies in China and the US, such as Nuokang Biopharma, Cathay Industrial Biotech, Xili Pharma, Wuhan Hiteck Biopharma, Chipscreen, Alpha Biopharma, Neurelis, Qpex, iGenomX and Jumpcode, etc.

Scroll to Top